- Advertisement -
Home NATION India’s first nasal COVID-19 vaccine ‘iNCOVACC’ officially unveiled by Health Minister Dr....

India’s first nasal COVID-19 vaccine ‘iNCOVACC’ officially unveiled by Health Minister Dr. Mansukh Mandaviya | Details here

iNCOVACC

iNCOVACC: On Thursday, Science and Technology Minister Jitendra Singh and Union Health Minister Dr. Mansukh Mandaviya introduced the first nasal COVID-19 vaccine in India, called “iNCOVACC.” Bharat Biotech is the manufacturer of the nasal COVID-19 vaccine. For “iNCOVACC,” a main two-dose regimen and a heterologous booster dosage have been authorised.

Also Read: Zagreb Open Grand Prix: Amidst tussles, Indian govt. approves 55-member team for highly-anticipated tournament

What is the price of iNCOVACC?

The price of iNCOVACC, according to Bharat Biotech, would be Rs 325 per dose for bulk purchases by the federal and state governments and Rs 800 per dose for private vaccination clinics. Everyone over the age of 18 will receive the vaccination as a booster shot, regardless of when they had their initial immunisation. There will be two doses, with a 28-day gap between them.

Krishna Ella, the Executive Chairman of Bharat Biotech, made an announcement last week on Saturday that the company’s nasal vaccination will officially be launched on January 26th, India’s Republic Day, during a gathering at Bhopal’s Maulana Azad National Institute of Technology. In December, Bharat Biotech’s nasal vaccination received approval from the Central Drugs Standard Control Organization. The National Technical Advisory Group on Immunization also proposed it as a “precautionary dosage” for adults as boosters.

Also Read: Renuka Singh: Star pacer bags ICC Women’s Emerging Cricketer of the Year award, beats several legendary players

Another vaccine to be launched next month

The vaccine was developed in collaboration with Washington University in St Louis and was tested in clinical trials with 875 participants across 9 locations in the country. The University had also created the recombinant adenoviral vector construct and conducted preclinical effectiveness tests, according to previous statements from Bharat Biotech.

Last Saturday, Bharat Biotech’s Executive Chairman, Ella, announced that the debut of Lumpi-ProVacind, a vaccine created by the Indian Council of Agriculture Research, is expected to be launched the following month. The Indian Council of Agriculture Research and Biovet, a subsidiary of Bharat Biotech based in Bangaluru, had entered into a contract for the commercial production of the vaccine in September of the previous year.

Keep watching our YouTube Channel ‘DNP INDIA’. Also, please subscribe and follow us on FACEBOOKINSTAGRAMand TWITTER

- Advertisement -
Exit mobile version